First-line chemotherapy with or without biologic agents for metastatic breast cancer

摘要: Abstract Breast cancer (BC) is one of the most important causes morbidity and mortality representing first tumor in female sex terms incidence third western world. An increased survival evident metastatic breast (MBC) as a result introduction novel therapeutic agents. Oncologists have several options available (chemotherapy, hormone-therapy biologic agents such anti-angiogenic anti-HER2 drugs) challenge nowadays individualization therapy (tailored approach). Despite better diagnostic tools new agents, at present main treatment goal MBC still palliation. Into attempt to tailor treatments, search for predictive factors deserves huge effort. This review faces different approaches first-line chemotherapy together with biological therapies recently approved this tumor.